Er Therapeutics Stock Retained Earnings
| PNGM Stock | USD 0.0001 0.00 0.00% |
Er Therapeutics fundamentals help investors to digest information that contributes to Er Therapeutics' financial success or failures. It also enables traders to predict the movement of PNGM Stock. The fundamental analysis module provides a way to measure Er Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Er Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Retained Earnings | -963.1 K | -914.9 K |
PNGM | Retained Earnings |
Er Therapeutics Company Retained Earnings Analysis
Er Therapeutics' Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
Current Er Therapeutics Retained Earnings | (914.9K) |
Most of Er Therapeutics' fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Er Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
| Competition |
PNGM Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Er Therapeutics' direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Er Therapeutics could also be used in its relative valuation, which is a method of valuing Er Therapeutics by comparing valuation metrics of similar companies.Er Therapeutics is currently under evaluation in retained earnings category among its peers.
PNGM Fundamentals
| Return On Asset | -0.95 | ||||
| Current Valuation | 122.36 K | ||||
| Shares Outstanding | 58.26 M | ||||
| Price To Earning | (0.06) X | ||||
| Price To Book | 143,650 X | ||||
| Net Income | (426.95 K) | ||||
| Cash And Equivalents | 650 | ||||
| Total Debt | 48.49 K | ||||
| Current Ratio | 0.01 X | ||||
| Book Value Per Share | (0) X | ||||
| Cash Flow From Operations | (161.43 K) | ||||
| Beta | 10.4 | ||||
| Market Capitalization | 332.11 K | ||||
| Total Asset | 423.6 K | ||||
| Working Capital | (638 K) | ||||
| Current Asset | 7 K | ||||
| Current Liabilities | 645 K | ||||
| Net Asset | 423.6 K |
About Er Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Er Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Er Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Er Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Er Therapeutics Piotroski F Score and Er Therapeutics Altman Z Score analysis. To learn how to invest in PNGM Stock, please use our How to Invest in Er Therapeutics guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Diversified Metals & Mining space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Er Therapeutics. If investors know PNGM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Er Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (0.95) |
The market value of Er Therapeutics is measured differently than its book value, which is the value of PNGM that is recorded on the company's balance sheet. Investors also form their own opinion of Er Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Er Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Er Therapeutics' market value can be influenced by many factors that don't directly affect Er Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Er Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Er Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Er Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.